Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.32
-12.37 (-5.55%)
AAPL  278.03
+2.12 (0.77%)
AMD  208.44
+15.94 (8.28%)
BAC  56.53
+1.59 (2.89%)
GOOG  323.10
-8.23 (-2.48%)
META  661.46
-8.75 (-1.31%)
MSFT  400.78
+7.11 (1.81%)
NVDA  185.41
+13.53 (7.87%)
ORCL  142.82
+6.34 (4.65%)
TSLA  411.11
+13.90 (3.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.